Trial Profile
P-REWARDS (Promus - Registry Experience at the Washington Hospital Center, DES).
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms P-REWARDS
- 15 Oct 2020 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 28 Mar 2013 Planned End Date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 28 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.